About US
Contact us
-
Teva exec: Euro price cuts may trigger generics shortagesEuropean price-cutting has caused many a branded drugmaker to lament. Now, generics giant Teva Pharmaceutical Industries ($TEVA) is getting into the act. The company's European chief warned that squee2012/5/4
-
IOM takes FDA to task on post-marketing safetyThe FDA doesn't do enough to track drugs' safety after they're on the market, government watchdogs at the Institute of Medicine say. To prevent another Vioxx-esque disaster, FDA should periodically2012/5/4
-
SFDA issues notice on effective utilization of ADR monitoring dataThe State Food and Drug Administration (SFDA) recently issued a notice on effective utilization of adverse drug reaction (ADR) monitoring data. The notice requires to make effective analysis, evaluati2012/5/2
-
SFDA further defines time limits for ophthalmic preparations to meet the requirements of newly revised GMPThe State Food and Drug Administration (SFDA) recently issued a notice to further define time limits for ophthalmic preparations and related products to meet the requirements of newly revised GMP.In a2012/5/2
-
Novartis digs into safety data in Avastin-vs.-Lucentis studyNovartis ($NVS) couldn't let the Avastin-vs.-Lucentis study pass by without comment. Two-year data from that head-to-head trial, funded by the National Eye Institute, showed that the two drugs were ev2012/5/3
-
Pfizer settles Celebrex royalty suit for $450MIt took almost 6 years, but Pfizer ($PFE) and Brigham Young University have finally come to terms. The drugmaker agreed to pay $450 million to settle a lawsuit claiming that BYU deserved billions in r2012/5/3
-
Under pressure, Brennan bows out as AstraZeneca CEOThe David Brennan era at AstraZeneca ($AZN) is over. The company's board, pressured by restless investors, asked Brennan to bow out yesterday, BBC News reports. The board also invited Chairman Louis S2012/4/28
-
Pfizer, Roche, GSK said to be knocking heads with generics on EU drug trackingA proposal by the European Union to require unique identifiers on drug packages to fight counterfeiting has sparked a fight between branded makers that say OK and generics companies that claim that it2012/4/28
-
Rumors put Bayer, Onyx at the M&A altarWith the Watson Pharmaceuticals-Actavis deal wrapped up, M&A hounds need something new to sniff out. And voilá! Reuters sources come through with a putative multibillion-euro Bayer Healthcare deal2012/4/27
-
SFDA further defines time limits for ophthalmic preparations to meet the requirements of newly revised GMPThe State Food and Drug Administration (SFDA) recently issued a notice to further define time limits for ophthalmic preparations and related products to meet the requirements of newly revised GMP.In a2012/4/27